
13 Jul 2026
Lysol x National PTA Launch HFHS QTO Grant
Lysol, in collaboration with National PTA, Launches HERE for Healthy Schools: Quality Time Off Grant to Help Families…
LA Kings Score Mucinex as First-Ever Official Cold and Flu Medicine Partner to Help Fans Power Through and Never Miss a Moment
New Partnership Brings Mucinex Kickstart’s Fast Relief, In-Game Experiences, and High-Energy Spirit to Kings Fans This NHL Season
PARSIPPANY, N.J., Oct. 16, 2025 – Two-time Stanley Cup Champions the LA Kings and Mucinex, the #1 most trusted brand among physicians for cough and cold symptoms*, are teaming up for a game-changing partnership designating Mucinex Kickstart as the “Official Cold and Flu Medicine” of the team. As the Kings’ hit the ice for another exciting season, this partnership, brokered by AEG Global Partnerships, introduces bold and innovative in-game moments and unforgettable experiences energizing fans all season long.
Mucinex Kickstart is designed to help fans, and players alike, power through cold and flu symptoms with fast, multi-symptom relief with an instant cooling sensation. Whether you’re cheering from the stands or the couch, Mucinex Kickstart helps ensure fans don’t miss a single play – even when those cold and flu symptoms try to take them out of the game.
Through this partnership, Mucinex will be woven into the Kings fan experience in fresh and engaging ways:
"Mucinex brings a unique energy and personality that aligns perfectly with our commitment to creating memorable fan experiences," said Josh Veilleux, senior vice president, AEG Global Partnerships. "This partnership goes beyond a traditional partnership by integrating creative elements like Mr. Mucus into our game presentation, adding entertainment value while addressing a real need our fans have during hockey season."
From powering fans through cold & flu season to fueling unforgettable moments in the stands, the LA Kings and Mucinex are teaming up to kickstart relief, so fans never miss a moment on or off the ice.
* IQVIA, ProVoice Survey, fielded to 3,930 physicians, September 1-December 31, 2024
